A Randomised Multicentre Trial Of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy In Combination With Rituximab (Mabthera®) For Stage I – II Low Grade Follicular Lymphoma
For patients with stage I and II low grade follicular lymphoma radiotherapy will cure 40-50% of cases. This study is comparing standard therapy (radiotherapy) and investigational therapy (radiotherapy plus chemotherapy) to see if adding chemotherapy extends the time until the lymphoma progresses in those patient that will not be cured.
Primary Sponsor
Trans Tasman Radiation Oncology Group (TROG)
Collaborating Groups
ALLG (NHLLOW 5); Princess Margaret Hospital, Toronto
Final Accrual
150
Closing Date of Accrual
July 2012
Trial Chairperson
A/Prof Michael Mac Manus, Peter MacCallum Cancer Centre, VIC
Trial Contact
Bev.McClure@petermac.org
Clinical Trial Registration
Related Post
October 18, 2022
NINJA Radiation Therapy Trial participant tells his journey to treatment
The journey to becoming the 200th participant for the
September 6, 2022
The gift that kept on giving
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
